Answers are grounded in this paper and cite their sources.
The Journal of Antimicrobial Chemotherapy was launched in 1975, just 4 years after the inauguration of the BSAC. In the first Editorial, Professor J. D. Williams made ‘no apology for the appearance of yet another journal’ (Figure 1). The Journal set out to cater to a broad church of disciplines involved in the development and use of antibiotics and related agents, attracting authors and readers from the BSAC and beyond. First Editorial by J. D. Williams. Journal of Antimicrobial Chemotherapy 1975; 1: 1–5. To mark its 40th anniversary, a series of articles has been specially commissioned to reflect on whether the Journal has fulfilled the ambitions of its founders and to measure its contribution to the field as a whole. These articles will appear in every issue throughout this year, with the Garrod Lecture being given pride of place. There will also be a special Supplement to mark the occasion. Very early on, the Journal attracted readers and authors far beyond the shores of the British Isles. This yielded rewards, but also posed challenges in so far as the ‘owner’ is British while the Journal is ‘international’. Far from proving detrimental, this has helped keep the Journal on its toes. Indeed, it has gone from strength to strength in terms of the number of submissions, the number of articles published and its impact factor (Figure 2). Editors-in-Chief of the Journal, published article numbers and impact factors. Editors-in-Chief (years served), from left to right: J. D. Williams (1975–80), Ian Phillips (1981–85), David Speller (1986–90), Roger Finch (1991–95), Martin Wood (1996–2000), David Reeves (2001–06) and Alan Johnson (2006–14). In his Editorial, Professor Williams stated, ‘The knowledge of the capabilities of antibiotics is still essential to control infections which nowadays are more complex and often occur in patients whose defences are compromised by other forms of medical and surgical treatment.’ If anything, the intervening years have shown how prescient this statement was, as the number of vulnerable patients continues to increase across the globe. The 40 years before the Journal's first appearance had already seen an explosive growth in knowledge of what antimicrobials were capable of achieving in terms of controlling and curing infection, even for patients whose defences were compromised by medical and surgical treatment. There was also a parallel growth in the number and range of antimicrobial agents. Such was the optimism that it led some to believe that it was ‘time to close the book on infectious diseases, and declare the war against pestilence won’. This urban myth, wrongly attributed to a Surgeon General of the USA, has since given way to the fear that increasing antimicrobial resistance might herald the end of the antimicrobial era altogether. Hence, drug discovery has given way to research into conservation, repurposing and stewardship. The types of articles the Journal has published have essentially remained unchanged (with the bulk reporting original research), but there are still plenty of review articles and leading articles offering opinions. Styles have also changed, with greater emphasis being placed on supplying new information and perhaps much less on imparting knowledge. The Journal still encourages articles that reflect on current issues and contentious matters. However, there seems to be less appetite for these than 40 years ago (among authors at least), probably because there is less time for contemplation and greater pressures to ‘publish or perish’. During the coming year, there will be plenty to celebrate and reflect upon as the Journal looks forward to the next four decades. Of course, there would be no Journal without readers and authors, nor would it have achieved the high standard that it has without the dedication of all the peer reviewers and Editors throughout the years, the devotion of the Journal staff and, of course, the energy and vision of my predecessors. It only remains for me to thank the BSAC for entrusting me with the task of honouring their legacy and navigating the Journal through the next few years. None to declare.
No takes yet. Share an insight, caveat, or question.
J. Peter Donnelly (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: